Latest news with #AGSM
Yahoo
23-06-2025
- Business
- Yahoo
GENOMMA LAB INTERNACIONAL ANNOUNCES TWELFTH DIVIDEND PAYMENT
MEXICO CITY, June 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 24, 2025 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis. About Genomma Lab Internacional Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low–cost, highly flexible supply chain operating model. For more information visit: Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM). Note on Forward-Looking Statements This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. View original content: SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Associated Press
12-06-2025
- Business
- Associated Press
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and Special Meeting ('AGSM'), which was held on Wednesday, June 11 th, 2025, at the Company's head office in Toronto, Ontario, Canada. Following shareholder approval on various resolutions and formal conclusion of the AGSM meeting, Theralase® hosted a virtual corporate presentation via Zoom to provide shareholders with an in-depth overview of the Company's strategic objectives and upcoming milestones for 2025 and 2026. The presentation highlighted current and planned clinical development programs focused on accelerating the commercialization of Theralase®'s innovative therapeutic technologies. For those unable to attend the live virtual session, an archived recording of the presentation can be accessed via the following link: Watch the AGSM Virtual Presentation here: AGSM Virtual Presentation Recording - Presented June 11th, 2025 Theralase® wishes to thank its shareholders and stakeholders for their ongoing support as the Company advances on its mission to commercialize safe and effective therapeutics to destroy various cancers, bacteria and viruses, with minimal impact on healthy tissue. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Yahoo
11-06-2025
- Business
- Yahoo
CaNickel Announces Shareholder Approval of All Resolutions at AGSM; to Delist from the TSXV on June 26, 2025
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - CaNickel Mining Limited (TSXV: CML) ("CaNickel" or the "Company") announces that, further to its press release on May 7, 2025, shareholders have approved all resolutions put forth at the Company's Annual General and Special Meeting ("AGSM"), which was held in Vancouver, BC, on June 11, 2025. This included the passing of an Ordinary Resolution, by a majority of the minority shareholders of the Company, authorizing the voluntary delisting of the Company's common shares from the TSX Venture Exchange ("TSXV"). The Company expects the delisting to occur at the close of business on Thursday, June 26, 2025, subject to final TSXV approval. At the AGSM, a total of 29,212,122 common shares were represented by proxy, representing 77.86% of the Company's outstanding common shares. The final voting results of the meeting are set out below. Election of Directors Shareholders have elected Wenfeng Liu, Shirley Anthony and James Dai to serve as directors until the next annual meeting of shareholders, or until their respective successors are elected or appointed. Myles Gao, Lorne Waldman, Kevin Zhu and Weiliang Wang did not stand for renomination to the Board. The Company extends its sincere gratitude to all outgoing directors for their invaluable contributions and wishes them continued success in their current and future endeavors. The table below sets forth the vote of the shareholders at the AGSM with respect to the election of directors: Nominee For Abstained Wenfeng Liu 99.842% 0.158% Shirley Anthony 99.817% 0.183% James Dai 99.809% 0.191% Appointment of Auditor Shareholders have approved the appointment of Baker Tilly WM LLP as auditor of the Company to hold office until the close of the next annual meeting of shareholders at such remuneration as may be fixed by the directors of the company. The table below sets forth the vote of the shareholders at the AGSM with respect to the appointment of the auditor: Appointment of Auditor For Abstained Baker Tilly WM LLP 99.960% 0.040% Voluntary TSX Venture Exchange Delisting An ordinary resolution has been approved by a majority of the minority shareholders of the Company authorizing the voluntary delisting of the Company's common shares from the TSXV. Excluding directors, officers, promoters, and shareholders holding 10% or more of the Company's common shares and their Associates and Affiliates ("Non-Arm's Length Parties" as defined in TSXV Policy 1.1.), a total of 15,043,782 shares were voted by disinterested shareholders on the resolution and the table below sets forth the voting results: Ordinary Resolution For Against Approval of Voluntary Delisting from the TSXV 99.588% 0.412% Under TSXV policies, delisting of a listed company when the company does not have an alternative public market requires majority of minority approval, meaning that directors, officers, promoters, and shareholders holding 10% or more of the Company's common shares and Non-Arm's Length Parties were not permitted to vote. Also excluded from the vote were King Place Enterprises Limited, which holds 11,517,653 shares, as well as its affiliate company, Hebei Wenfeng Industrial Group, which holds 2,587,500 shares. The total number of shares that were excluded from voting on the resolution was 14,105,153, representing 37.6% of the total number of shares outstanding. With the passing of the resolution, along with Board approval of the delisting on April 22, 2025, the Company will proceed to finalize the process of voluntarily delisting from the TSXV. The delisting is expected to occur at the close of business on Thursday, June 26, 2025, subject to final TSXV approval. The Company will remain a reporting issuer in Canada and will continue to comply with its continuous disclosure obligations under applicable securities laws. ABOUT CANICKEL CaNickel Mining Limited is a Canadian junior mining company that currently owns the Bucko Lake Mine, currently on care and maintenance, near Wabowden, Manitoba. From 2009 to 2012, nearly 450,000 tonnes of mineralized material were mined to produce 6.9 million pounds of nickel before the mine was put on care and maintenance due to low nickel prices. Further information is available at or contact: Shirley AnthonyChief Executive OfficerPhone: 778-999-2771 CaNickel Mining LimitedSuite 720 - 320 Granville British Columbia Canada V6C 1S9 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
05-06-2025
- Business
- Associated Press
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ('AGSM') to take place on Wednesday, June 11 th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada. In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed. The corporate power point presentation and question and answer period will end at 6:30 pm ET. Zoom Meeting Link: Webinar ID: 871 7513 9183 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom. An archived version will be available on the website, the next business day, following the conference call. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Yahoo
05-06-2025
- Business
- Yahoo
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ("AGSM") to take place on Wednesday, June 11th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada. In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed. The corporate power point presentation and question and answer period will end at 6:30 pm ET. Zoom Meeting Link: ID: 871 7513 9183Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom. An archived version will be available on the website, the next business day, following the conference call. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit
